https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-20 / PLoS ONE 2011 Apr;6(4):e18801
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-20 / PLoS ONE 2011 Apr;6(4):e188012011-04-20 00:00:002019-02-15 08:53:13Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-06 / J. Virol. 2011 Jun;85(12):6015-23
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-06 / J. Virol. 2011 Jun;85(12):6015-232011-04-06 00:00:002019-02-15 09:21:40Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-06 / Arch. Virol. 2011 Aug;156(8):1335-44
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-06 / Arch. Virol. 2011 Aug;156(8):1335-442011-04-06 00:00:002011-04-06 00:00:00Caspase- and p38-MAPK-dependent induction of apoptosis in A549 lung cancer cells by Newcastle disease virus
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-05 / Mol. Ther. 2011 Aug;19(8):1558-68
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-05 / Mol. Ther. 2011 Aug;19(8):1558-682011-04-05 00:00:002019-02-15 08:40:06Optimizing DC vaccination by combination with oncolytic adenovirus coexpressing IL-12 and GM-CSF
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-01 / Immunotherapy 2011 Apr;3(4):569-76
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-01 / Immunotherapy 2011 Apr;3(4):569-762011-04-01 00:00:002019-02-15 08:45:54Chronic myeloid leukemia lysate-loaded dendritic cells induce T-cell responses towards leukemia progenitor cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-04-01 / G Ital Dermatol Venereol 2011 Apr;146(2):103-13
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-04-01 / G Ital Dermatol Venereol 2011 Apr;146(2):103-132011-04-01 00:00:002019-02-15 08:48:39Dendritic cells and cutaneous T-cell lymphomas
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-29 / Oncol. Rep. 2011 Jun;25(6):1573-9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-29 / Oncol. Rep. 2011 Jun;25(6):1573-92011-03-29 00:00:002011-03-29 00:00:00Effect of hyperthermia on invasion ability and TGF-β1 expression of breast carcinoma MCF-7 cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-25 / Eur. J. Cell Biol. 2012 Jan;91(1):53-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-25 / Eur. J. Cell Biol. 2012 Jan;91(1):53-82011-03-25 00:00:002019-02-15 08:40:02Third generation dendritic cell vaccines for tumor immunotherapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-29
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-17 / Int. J. Oncol. 2011 Jun;38(6):1719-292011-03-17 00:00:002021-11-15 16:59:03Targeting of IL-2 and GM-CSF immunocytokines to a tumor vaccine leads to increased anti-tumor activity
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2011-03-02 / Cancer Immunol. Immunother. 2011 Jun;60(6):809-18
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2011-03-02 / Cancer Immunol. Immunother. 2011 Jun;60(6):809-182011-03-02 00:00:002019-02-15 08:40:07hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
